Share-based Payment Arrangement, Expense of ENANTA PHARMACEUTICALS INC from 30 Sep 2014 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
ENANTA PHARMACEUTICALS INC quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 30 Sep 2014 to 30 Sep 2025.
  • ENANTA PHARMACEUTICALS INC Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $4,034,000, a 48% decline year-over-year.
  • ENANTA PHARMACEUTICALS INC Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $18,565,000, a 31% decline year-over-year.
  • ENANTA PHARMACEUTICALS INC annual Share-based Payment Arrangement, Expense for 2025 was $18,565,000, a 31% decline from 2024.
  • ENANTA PHARMACEUTICALS INC annual Share-based Payment Arrangement, Expense for 2024 was $26,795,000, a 5% decline from 2023.
  • ENANTA PHARMACEUTICALS INC annual Share-based Payment Arrangement, Expense for 2023 was $28,216,000, a 4.6% increase from 2022.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

ENANTA PHARMACEUTICALS INC Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $18,565,000 $4,034,000 -$3,684,000 -48% 01 Jul 2025 30 Sep 2025 10-K 19 Nov 2025 2025 FY
Q2 2025 $22,249,000 $4,177,000 -$1,240,000 -23% 01 Apr 2025 30 Jun 2025 10-Q 13 Aug 2025 2025 Q3
Q1 2025 $23,489,000 $4,688,000 -$873,000 -16% 01 Jan 2025 31 Mar 2025 10-Q 14 May 2025 2025 Q2
Q4 2024 $24,362,000 $5,666,000 -$2,433,000 -30% 01 Oct 2024 31 Dec 2024 10-Q 12 Feb 2025 2024 Q1
Q3 2024 $26,795,000 $7,718,000 +$1,002,000 +15% 01 Jul 2024 30 Sep 2024 10-K 19 Nov 2025 2025 FY
Q2 2024 $25,793,000 $5,417,000 -$1,581,000 -23% 01 Apr 2024 30 Jun 2024 10-Q 13 Aug 2025 2025 Q3
Q1 2024 $27,374,000 $5,561,000 -$1,802,000 -24% 01 Jan 2024 31 Mar 2024 10-Q 14 May 2025 2025 Q2
Q4 2023 $29,176,000 $8,099,000 +$960,000 +13% 01 Oct 2023 31 Dec 2023 10-Q 12 Feb 2025 2024 Q1
Q3 2023 $28,216,000 $6,716,000 -$117,000 -1.7% 01 Jul 2023 30 Sep 2023 10-K 19 Nov 2025 2025 FY
Q2 2023 $28,333,000 $6,998,000 -$605,000 -8% 01 Apr 2023 30 Jun 2023 10-Q 07 Aug 2024 2024 Q3
Q1 2023 $28,938,000 $7,363,000 +$892,000 +14% 01 Jan 2023 31 Mar 2023 10-Q 08 May 2024 2024 Q2
Q4 2022 $28,046,000 $7,139,000 +$1,077,000 +18% 01 Oct 2022 31 Dec 2022 10-Q 08 Feb 2024 2024 Q1
Q3 2022 $26,969,000 $6,833,000 +$1,480,000 +28% 01 Jul 2022 30 Sep 2022 10-K 27 Nov 2024 2024 FY
Q2 2022 $25,489,000 $7,603,000 +$2,128,000 +39% 01 Apr 2022 30 Jun 2022 10-Q 08 Aug 2023 2023 Q3
Q1 2022 $23,361,000 $6,471,000 +$1,191,000 +23% 01 Jan 2022 31 Mar 2022 10-Q 09 May 2023 2023 Q2
Q4 2021 $22,170,000 $6,062,000 +$1,179,000 +24% 01 Oct 2021 31 Dec 2021 10-Q 08 Feb 2023 2023 Q1
Q3 2021 $20,991,000 $5,353,000 +$608,000 +13% 01 Jul 2021 30 Sep 2021 10-K 22 Nov 2023 2023 FY
Q2 2021 $20,383,000 $5,475,000 +$720,000 +15% 01 Apr 2021 30 Jun 2021 10-Q 08 Aug 2022 2022 Q3
Q1 2021 $19,663,000 $5,280,000 +$303,000 +6.1% 01 Jan 2021 31 Mar 2021 10-Q 09 May 2022 2022 Q2
Q4 2020 $19,360,000 $4,883,000 -$215,000 -4.2% 01 Oct 2020 31 Dec 2020 10-Q 10 Feb 2022 2022 Q1
Q3 2020 $19,575,000 $4,745,000 +$233,000 +5.2% 01 Jul 2020 30 Sep 2020 10-K 23 Nov 2022 2022 FY
Q2 2020 $19,342,000 $4,755,000 +$591,000 +14% 01 Apr 2020 30 Jun 2020 10-Q 09 Aug 2021 2021 Q3
Q1 2020 $18,751,000 $4,977,000 +$270,000 +5.7% 01 Jan 2020 31 Mar 2020 10-Q 10 May 2021 2021 Q2
Q4 2019 $18,481,000 $5,098,000 -$745,000 -13% 01 Oct 2019 31 Dec 2019 10-Q 09 Feb 2021 2021 Q1
Q3 2019 $19,226,000 $4,512,000 +$402,000 +9.8% 01 Jul 2019 30 Sep 2019 10-K 24 Nov 2021 2021 FY
Q2 2019 $18,824,000 $4,164,000 +$139,000 +3.5% 01 Apr 2019 30 Jun 2019 10-Q 10 Aug 2020 2020 Q3
Q1 2019 $18,685,000 $4,707,000 +$1,117,000 +31% 01 Jan 2019 31 Mar 2019 10-Q 11 May 2020 2020 Q2
Q4 2018 $17,568,000 $5,843,000 +$1,723,000 +42% 01 Oct 2018 31 Dec 2018 10-Q 10 Feb 2020 2020 Q1
Q3 2018 $15,845,000 $4,110,000 +$900,000 +28% 01 Jul 2018 30 Sep 2018 10-K 25 Nov 2020 2020 FY
Q2 2018 $14,945,000 $4,025,000 +$923,000 +30% 01 Apr 2018 30 Jun 2018 10-Q 09 Aug 2019 2019 Q3
Q1 2018 $14,022,000 $3,590,000 +$98,000 +2.8% 01 Jan 2018 31 Mar 2018 10-Q 10 May 2019 2019 Q2
Q4 2017 $13,924,000 $4,120,000 +$853,000 +26% 01 Oct 2017 31 Dec 2017 10-Q 08 Feb 2019 2019 Q1
Q3 2017 $13,071,000 $3,210,000 +$700,000 +28% 01 Jul 2017 30 Sep 2017 10-K 27 Nov 2019 2019 FY
Q2 2017 $12,371,000 $3,102,000 +$632,000 +26% 01 Apr 2017 30 Jun 2017 10-Q 09 Aug 2018 2018 Q3
Q1 2017 $11,739,000 $3,492,000 +$1,110,000 +47% 01 Jan 2017 31 Mar 2017 10-Q 10 May 2018 2018 Q2
Q4 2016 $10,629,000 $3,267,000 +$1,275,000 +64% 01 Oct 2016 31 Dec 2016 10-Q 09 Feb 2018 2018 Q1
Q3 2016 $9,354,000 $2,510,000 01 Jul 2016 30 Sep 2016 10-K 29 Nov 2018 2018 FY
Q2 2016 $2,470,000 01 Apr 2016 30 Jun 2016 10-Q 09 Aug 2017 2017 Q3
Q1 2016 $2,382,000 01 Jan 2016 31 Mar 2016 10-Q 10 May 2017 2017 Q2
Q4 2015 $1,992,000 01 Oct 2015 31 Dec 2015 10-Q 09 Feb 2017 2017 Q1

ENANTA PHARMACEUTICALS INC Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $18,565,000 -$8,230,000 -31% 01 Oct 2024 30 Sep 2025 10-K 19 Nov 2025 2025 FY
2024 $26,795,000 -$1,421,000 -5% 01 Oct 2023 30 Sep 2024 10-K 19 Nov 2025 2025 FY
2023 $28,216,000 +$1,247,000 +4.6% 01 Oct 2022 30 Sep 2023 10-K 19 Nov 2025 2025 FY
2022 $26,969,000 +$5,978,000 +28% 01 Oct 2021 30 Sep 2022 10-K 27 Nov 2024 2024 FY
2021 $20,991,000 +$1,416,000 +7.2% 01 Oct 2020 30 Sep 2021 10-K 22 Nov 2023 2023 FY
2020 $19,575,000 +$349,000 +1.8% 01 Oct 2019 30 Sep 2020 10-K 23 Nov 2022 2022 FY
2019 $19,226,000 +$3,381,000 +21% 01 Oct 2018 30 Sep 2019 10-K 24 Nov 2021 2021 FY
2018 $15,845,000 +$2,774,000 +21% 01 Oct 2017 30 Sep 2018 10-K 25 Nov 2020 2020 FY
2017 $13,071,000 +$3,717,000 +40% 01 Oct 2016 30 Sep 2017 10-K 27 Nov 2019 2019 FY
2016 $9,354,000 +$3,516,000 +60% 01 Oct 2015 30 Sep 2016 10-K 29 Nov 2018 2018 FY
2015 $5,838,000 +$3,156,000 +118% 01 Oct 2014 30 Sep 2015 10-K 11 Dec 2017 2017 FY
2014 $2,682,000 01 Oct 2013 30 Sep 2014 10-K 09 Dec 2016 2016 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.